TMDX EBITDA | TransMedics Group, Inc.

TransMedics Group, Inc. (TMDX) EBITDA

2026-06-30: Basis Reported; EBITDA $33.98M*; Operating income $23.74M; Depreciation and amortization $10.24M*.
2026-03-31: Basis Reported; EBITDA $25.16M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $28.74M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $30.15M*; Operating income $23.30M; Depreciation and amortization $6.85M*.

Complete source-backed ebitda history.

Available history: 2018-03-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$33.98M*	$23.74M	$10.24M*	(m)	(m)	$7.09M*	$17.31M*	(m)	$31.63M	$57.83M	$4.72M
2026-03-31	Reported	$25.16M	(m)	(m)	(m)	14.47%	$36.66M	$24.53M	(m)	$24.88M	$62.98M	$1.17M
2025-12-31	Reported	$28.74M	(m)	(m)	(m)	17.88%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$30.15M*	$23.30M	$6.85M*	(m)	(m)	$7.62M*	$69.57M*	(m)	$15.26M	$46.02M	-$1.29M
2025-06-30	Reported	$43.30M*	$36.57M	$6.73M*	(m)	(m)	$9.07M*	$91.61M*	(m)	$15.93M	$44.09M	$1.27M
2025-03-31	Reported	$33.58M	(m)	(m)	(m)	23.39%	$27.04M	-$2.85M	(m)	$17.16M	$43.63M	$994.00K
2024-12-31	Reported	$14.32M	(m)	(m)	(m)	11.78%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$9.10M*	$3.92M	$5.18M*	(m)	(m)	$48.20M*	$6.86M*	(m)	$14.27M	$42.66M	$29.00K
2024-06-30	Reported	$17.11M*	$12.51M	$4.60M*	(m)	(m)	$23.76M*	$25.72M*	(m)	$13.86M	$42.90M	-$41.00K
2024-03-31	Reported	$16.72M	(m)	(m)	(m)	17.27%	$44.17M	-$3.44M	(m)	$11.38M	$36.16M	$196.00K
2023-12-31	Reported	$6.21M	(m)	(m)	(m)	7.65%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$26.44M*	-$28.34M	$1.89M*	(m)	(m)	$107.72M*	-$6.87M*	(m)	$11.13M	$30.65M	(m)
2023-06-30	Reported	$486.00K*	-$906.00K	$1.39M*	(m)	(m)	$1.38M*	-$5.80M*	(m)	$8.29M	$29.36M	(m)
2023-03-31	Reported	-$802,000.00	(m)	(m)	(m)	-1.93%	$927.00K	-$8.66M	(m)	$5.87M	$24.98M	(m)
2022-12-31	Reported	-$5.49M	(m)	(m)	(m)	-16.77%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$4.65M*	-$5.54M	$891.00K*	$24.30M	-19.15%*	$2.93M*	-$14.28M*	(m)	$6.81M	$16.85M	(m)
2022-06-30	Reported	-$8.95M*	-$9.74M	$795.00K*	$20.52M	-43.61%*	$4.26M*	-$9.09M*	(m)	$6.71M	$17.38M	(m)
2022-03-31	Reported	-$8.86M	(m)	(m)	(m)	-55.81%	$1.95M	-$18.41M	(m)	$7.53M	$13.94M	(m)
2021-12-31	Reported	-$10.86M	(m)	(m)	(m)	-112.35%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$11.27M*	-$11.72M	$455.00K*	$5.41M	-208.20%*	$68.00K*	-$9.35M*	(m)	$5.16M	$10.34M	(m)
2021-06-30	Reported	-$9.42M*	-$9.87M	$451.00K*	$8.67M	-108.65%*	$253.00K*	-$5.54M*	(m)	$6.29M	$9.16M	(m)
2021-03-31	Reported	-$6.06M	(m)	(m)	(m)	-79.38%	$20.00K	-$7.33M	(m)	$4.53M	$6.79M	(m)
2020-12-31	Reported	-$5.47M	(m)	(m)	(m)	-66.52%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$4.21M*	-$4.61M	$402.00K*	$7.97M	-52.78%*	$56.00K*	-$6.41M*	(m)	$4.16M	$5.49M	(m)
2020-06-30	Reported	-$7.49M*	-$7.86M	$374.00K*	$3.92M	-190.85%*	$120.00K*	-$8.54M*	(m)	$3.90M	$5.87M	(m)
2020-03-31	Reported	-$7.65M	(m)	(m)	(m)	-92.76%	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-28	Reported	-$8.34M	(m)	(m)	(m)	-129.01%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-28	Reported	-$6.91M*	-$7.24M	$332.00K*	$7.88M	-87.73%*	$33.00K*	-$5.60M*	(m)	$4.94M	$6.52M	(m)
2019-06-29	Reported	-$7.42M*	-$7.71M	$289.00K*	$6.21M	-119.32%*	$148.00K*	-$12.16M*	(m)	$4.79M	$6.25M	(m)
2019-03-30	Reported	-$5.72M	(m)	(m)	(m)	-108.07%	$3.00K	-$7.27M	(m)	$3.88M	$4.65M	(m)
2018-12-29	Reported	(m)	-$6.36M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-29	Reported	(m)	-$3.94M	(m)	$4.75M	(m)	(m)	(m)	(m)	$3.27M	$2.80M	(m)
2018-06-30	Reported	-$4.99M*	-$5.16M	$171.00K*	$3.26M	-152.73%*	$0.00*	-$7.47M*	(m)	$3.43M	$2.90M	(m)
2018-03-31	Reported	-$4.62M	(m)	(m)	(m)	-167.45%	$40.00K	-$6.33M	(m)	$3.46M	$2.24M	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$135.77M	(m)	(m)	(m)	22.42%	$59.25M	$192.84M	(m)	$69.06M	$185.17M	-$82.77M
2024-12-31	Reported	$57.25M	(m)	(m)	(m)	12.97%	$129.74M	$48.80M	(m)	$55.97M	$168.62M	$316.00K
2023-12-31	Reported	-$20.55M	(m)	(m)	(m)	-8.50%	$151.85M	-$13.03M	(m)	$36.05M	$119.55M	-$1.64M
2022-12-31	Reported	-$27.96M	(m)	(m)	(m)	-29.92%	$11.91M	-$45.82M	(m)	$26.81M	$69.90M	$66.00K
2021-12-31	Reported	-$37.61M	(m)	(m)	(m)	-119.84%	$3.52M	-$28.86M	(m)	$22.30M	$38.28M	(m)
2021-09-30	Rolling	(m)	-$34.00M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$26.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$24.87M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$24.81M	(m)	(m)	(m)	-87.48%	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-28	Reported	-$28.38M	(m)	(m)	(m)	-109.82%	$165.00K	-$32.29M	(m)	$19.87M	$23.60M	$0.00
2019-12-28	Rolling	(m)	-$29.60M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-28	Rolling	(m)	-$27.27M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-29	Rolling	(m)	-$23.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-30	Rolling	(m)	-$21.42M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-29	Reported	-$19.47M	(m)	(m)	(m)	-132.82%	$418.00K	-$25.98M	(m)	$13.66M	$12.31M	$0.00
2018-12-29	Rolling	(m)	-$20.24M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Axogen, Inc. (AXGN)	United States	$2.329B	-73.83
BIOLIFE SOLUTIONS INC (BLFS)	United States	$1.887B	23.80
LivaNova PLC (LIVN)		$4.158B	24.01
Integer Holdings Corp (ITGR)	United States	$4.289B	25.17
CONMED Corp (CNMD)	United States	$1.353B	26.72
Ceribell, Inc. (CBLL)	United States	$0.916B	-11.27
CapsoVision, Inc (CV)	United States	$0.310B	-12.68
Electromed, Inc. (ELMD)	United States	$0.233B	31.13
EDAP TMS SA (FOCL)		$0.171B
Stereotaxis, Inc. (STXS)	United States	$0.130B	-7.53